Nicholas Lydon
http://dbpedia.org/resource/Nicholas_Lydon an entity of type: Thing
Nicholas B. Lydon (* 27. Februar 1957) ist ein US-amerikanischer Biochemiker und Geschäftsmann.
rdf:langString
Nicholas B. Lydon, né le 27 février 1957, est un biochimiste et un homme d'affaires britannique.
rdf:langString
Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
rdf:langString
尼古拉斯·B·莱登（英語：Nicholas B. Lydon，1957年2月27日－），英国科学家、企业家。他因研发格列卫——一种治疗慢性粒细胞白血病的选择性BCR - ABL抑制剂获得2009年拉斯克奖。莱登在英国利兹大学获生物化学理学士，在邓迪大学获得博士学位。
rdf:langString
rdf:langString
Nicholas B. Lydon
rdf:langString
Nicholas Lydon
rdf:langString
Nicholas Lydon
rdf:langString
尼古拉斯·莱登
rdf:langString
Nicholas Lydon
rdf:langString
Nicholas Lydon
xsd:date
1957-02-27
xsd:integer
25064040
xsd:integer
1075194215
rdf:langString
Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum
xsd:integer
1982
rdf:langString
Amgen
rdf:langString
Schering-Plough
rdf:langString
rdf:langString
Ciba-Geigy
rdf:langString
University of Dundee
rdf:langString
University of Leeds
rdf:langString
rdf:langString
rdf:langString
FRS
rdf:langString
Japan Prize
rdf:langString
Lasker Clinical Award
xsd:date
1957-02-27
rdf:langString
rdf:langString
Gleevec
rdf:langString
AnaptysBio
rdf:langString
BluePrint Medicines
rdf:langString
Nicholas B. Lydon (* 27. Februar 1957) ist ein US-amerikanischer Biochemiker und Geschäftsmann.
rdf:langString
Nicholas B. Lydon, né le 27 février 1957, est un biochimiste et un homme d'affaires britannique.
rdf:langString
Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
rdf:langString
尼古拉斯·B·莱登（英語：Nicholas B. Lydon，1957年2月27日－），英国科学家、企业家。他因研发格列卫——一种治疗慢性粒细胞白血病的选择性BCR - ABL抑制剂获得2009年拉斯克奖。莱登在英国利兹大学获生物化学理学士，在邓迪大学获得博士学位。
xsd:nonNegativeInteger
8829